BiomX
NESS ZIONA, L3 · Biotechnology, Healthcare, Health Care · 59 employees
BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Funding history
- Funding Round — $3.3M — Jan 2026
- Funding Round — $61.5M — Apr 2024
- Series seed — $1.5M — Mar 2023
- Series seed — $3.0M — Jan 2022
- Funding Round — $3.0M — Oct 2021
Recent signals
- Apr 10, 2026: Acquired BiomX acquires Zorronet for defense tech expansion
- Mar 11, 2026: SEC 8-K (5.07): On March 11, 2026, BiomX Inc. held a special meeting of stockholders, which was originally scheduled for February 25, 2026, but was adjourned to allow additional time for stockholder votes. As of the record date, February 3, 2026, there were 1,593,516 shares of common stock outstanding, all of which were eligible to vote at the meeting. The special meeting achieved quorum with all shares present either in person or by proxy, and no broker non-votes were recorded. The outcome of the proposals will impact the governance of the company and strategic decision-making moving forward.
- Mar 09, 2026: BiomX Appoints Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer
- Jan 20, 2026: Raised $3.3M
- Feb 26, 2025: BiomX Announces Financing of $12 Million to Advance BX004 Program in Cystic Fibrosis Patients
- Apr 01, 2024: Raised $61.5M
- Mar 03, 2023: Raised $1.5M in Series seed
- Jan 04, 2022: Raised $3.0M in Series seed
See plans & pricing → Track BiomX’s funding, hiring, and signals — with verified contacts — on Fundz.